Drug Discovery Today
JANUARY 10, 2023
Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions.
Antidote
JANUARY 12, 2023
Alzheimer’s disease is the most common type of dementia in the United States, impacting around 6.2 million people above the age of 65. Since it was first observed in the early 1900s, a lot of information has been uncovered through medical research.
Drug Channels
JANUARY 10, 2023
For 2023, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again increased the number of drugs they exclude from their standard formularies. Each exclusion list now contains about 600 products. Growth in the number of excluded drugs slowed for the second year, due partly to the fact that so many drugs have already been dropped from PBMs’ formularies.
Drug Patent Watch
JANUARY 7, 2023
Brimonidine tartrate is the generic ingredient in nine branded drugs marketed by Padagis Israel, Galderma Labs Lp, Allergan, Akorn, Apotex, Bausch And Lomb, Indoco, Sandoz Inc, Somerset Theraps Llc, Teva…. The post New tentative approval for Slayback Pharma drug brimonidine tartrate appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
New Drug Approvals
JANUARY 13, 2023
SC-52458, FORASARTAN Molecular FormulaC 23 H 28 N 8 Average mass416.522 Da PHASE 2, PFIZER, HYPERTENSION 145216-43-9 [RN] 5-[(3,5-Dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(1H-tetrazol-5-yl)phenyl]pyridine 5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]pyridine форасартан [Russian] [INN] , فوراسارتان [Arabic] [INN] , 福拉沙坦 [Chinese] [INN] 065F7WPT0B [DBID] 7415 [DBID] UNII-065F7WPT0B [DBID] SC 52458[DBID] Type-1 angiotensin II receptor Forasartan , otherwise
Cytel
JANUARY 13, 2023
Bayesian methods, with their ability to facilitate flexibility and learning, are often associated with early-phase clinical trials. Yet there are also many strategic uses of Bayesian methods in late-phase clinical trial design, which can help generate more effective, efficient, and ethical clinical trials.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
JANUARY 13, 2023
This chart shows the pharmaceutical companies with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.
Advarra
JANUARY 13, 2023
New privacy regulations seem to form every few months, especially with individual U.S. states adopting their own privacy regulations (e.g., the California Consumer Privacy Act or CCPA ). Endpoint adjudication committees (EACs), also called clinical event committees (CECs), receive potentially identifiable research data from all over the world. Because of this, they need to stay abreast of these rapidly developing requirements and have systems in place to ensure data compliance and protection.
Cytel
JANUARY 12, 2023
Statistical methods have long been fundamental to drug development, and advancements in the last few decades in computing power have opened the door to more widespread use of Bayesian methods in clinical trials. Interest in Bayesian methods is growing – in particular due to what these approaches enable. So why aren’t more clinicians using Bayesian methods?
ProRelix Research
JANUARY 12, 2023
In India, the Central Drugs Standard Control Organization (CDSCO) under the Directorate General of Health Services, Government of India is the National Regulatory Authority (NRA) responsible for the approval of […]. The post Clinical Trial Application and Import Requirement in India with respect to SUGAM portal appeared first on ProRelix Research.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
JANUARY 13, 2023
Annual Drug Patent Expirations for WINLEVI Winlevi is a drug marketed by Sun Pharm and is included in one NDA. It is available from one supplier. There are eight patents…. The post New patent for Sun Pharm drug WINLEVI appeared first on DrugPatentWatch - Make Better Decisions.
Crown Bioscience
JANUARY 11, 2023
It is well-known that drug attrition rates for anticancer agents are very high. In fact, only about 5% of compounds in preclinical development eventually becoming approved for clinical use. The need for more clinically relevant preclinical models has been identified as one of the areas that can reduce this attrition rate by enabling better decisions when selecting agents to advance to the clinic.
Advarra
JANUARY 10, 2023
As the clinical research industry becomes more centered on technology, perhaps one of its most underused solutions is the electronic consent (eConsent) platform. A valuable tool for both sites and participants, there are many benefits to adopting eConsent. This blog outlines why adopting an eConsent platform is a beneficial and strategic step sites can take right now. eConsent Gives Sites Flexibility.
Molecule Blog
JANUARY 9, 2023
The future of research is collaborative, digital, and highly autonomous. Patents today are not. We are building the intellectual property system that will help usher in this new era. IP-NFTs and Decentralized, Autonomous Science Today, most science is conducted at centralized institutions with a high barrier to entry and a reliance on imprecise human labor.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
JANUARY 13, 2023
Annual Drug Patent Expirations for SAVELLA Savella is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. There are two patents protecting…. The post New patent expiration for Allergan drug SAVELLA appeared first on DrugPatentWatch - Make Better Decisions.
DS in Pharmatics
JANUARY 7, 2023
Cell and gene therapies for treating multiple myeloma, such as CAR-T, have resulted in breakthrough health outcomes for patients. In the last decade, approval of cell and gene therapy (CGT) products has increased significantly.
Antidote
JANUARY 9, 2023
As a digital company, Antidote does not produce goods or services that have a major environmental impact — however, we understand that small changes still have a big impact.
Precision for Medicine
JANUARY 10, 2023
Precision for Medicine will be exhibiting at OCT Southeast in Raleigh NC. Contact us here to schedule a meeting or stop by out booth to meet the team! At OCT Southeast pharmaceutical, biotechnology, and medical device communities come together and discuss strategies for operational success in clinical trials The post OCT Southeast (March 28-29) appeared first on Precision For Medicine.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
JANUARY 12, 2023
This chart shows the pharmaceutical companies with the most patents in Malaysia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Malaysia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug & Device Law
JANUARY 7, 2023
As 2022 has come to an end, our loyal readers have joined us in reviewing our worst decisions of the past year and our best decisions of the past year. As we do each year, we’re pleased to announce that three of your bloggers – Bexis, Steven Boranian, and Rachel Weil – will be presenting a free 90-minute CLE webinar on “The good, the bad and the ugly: The best and worst drug/medical device decisions of 2022” on Thursday, January 19 th at 1 p.m.
Drug Patent Watch
JANUARY 12, 2023
Annual Drug Patent Expirations for PLENVU Plenvu is a drug marketed by Salix and is included in one NDA. It is available from one supplier. There are nine patents protecting…. The post New patent for SALIX drug PLENVU appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 12, 2023
Annual Drug Patent Expirations for EPINEPHRINE Epinephrine is a drug marketed by Armstrong Pharms, Am Regent, Bpi Labs, Intl Medication Sys, Hospira, and Teva Pharms Usa and, and is included…. The post New patent for Bpi Labs drug EPINEPHRINE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 11, 2023
This chart shows the pharmaceutical companies with the most patents in Japan. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Japan? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 11, 2023
Annual Drug Patent Expirations for WINLEVI Winlevi is a drug marketed by Sun Pharm and is included in one NDA. It is available from one supplier. There are eight patents…. The post New patent expiration for Sun Pharm drug WINLEVI appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 11, 2023
Annual Drug Patent Expirations for IBRANCE Ibrance is a drug marketed by Pfizer and is included in two NDAs. It is available from two suppliers. There are six patents protecting…. The post New patent for Pfizer drug IBRANCE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 11, 2023
Annual Drug Patent Expirations for TAGRISSO Tagrisso is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are three patents protecting…. The post New patent for Astrazeneca drug TAGRISSO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 10, 2023
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the…. The post Which pharmaceutical companies have supplementary protection certificates in the most countries? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 10, 2023
Annual Drug Patent Expirations for OLUMIANT Olumiant is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from one supplier. There are…. The post New patent for Eli Lilly drug OLUMIANT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 9, 2023
This chart shows the pharmaceutical companies with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 9, 2023
Annual Drug Patent Expirations for DEFINITY Definity is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Lantheus Medcl drug DEFINITY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 9, 2023
Annual Drug Patent Expirations for DEFINITY+RT Definity Rt is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are seven…. The post New patent for Lantheus Medcl drug DEFINITY RT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 9, 2023
Annual Drug Patent Expirations for SYMPAZAN Sympazan is a drug marketed by Otter Pharms and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Otter Pharms drug SYMPAZAN appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 9, 2023
Annual Drug Patent Expirations for GIVLAARI Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Alnylam Pharms drug GIVLAARI appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
113 
Let's personalize your content